
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is a promising company with a strong focus on developing oral, small molecule drugs for metabolic diseases such as diabetes and obesity. With a potentially effective drug candidate in icovamenib and a pipeline of other promising drugs, the company has significant potential for growth in the competitive diabetes market. However, the success of icovamenib will depend on the results of larger clinical trials and competition from other companies in the space.
Bears say
Biomea Fusion is a clinical-stage company focused on the development of oral, small molecule drugs for the treatment of diabetes, obesity, and metabolic diseases. While the potential for its lead drug candidate, icovamenib, to improve outcomes in diabetes and obesity is supported by compelling early data, the small sample size and upcoming Phase 2b data in 4Q26 creates uncertainty around its future prospects. Additionally, the company's other drug candidate, BMF-650, has potential upside but faces competition in the crowded GLP market and has yet to report data in its Phase 1 trial. The overall risk/reward for the company may skew positively from current levels, but there are still several key catalysts to watch in the coming quarters.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares